Results 241 to 250 of about 1,157,757 (252)

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial

European Journal of Cancer, 2021
Gudrun Schleiermacher, Caroline Brard, Xavier Paoletti   +2 more
exaly  

Perspective: The expanding challenge of HIV-associated malignancies

Ca-A Cancer Journal for Clinicians, 1992
Samuel Broder, J E Karp, S Broder
exaly  

Staging of Primary Malignancies of Bone†

Ca-A Cancer Journal for Clinicians, 2006
Terrance Peabody, M A Simon, Michael A Simon   +2 more
exaly  

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies Free

Blood, 2018
Ian W. Flinn, Susan O'Brien, Jan A Burger   +2 more
exaly  

Synchronous dual hematological malignancies: new or underreported entity?

Hematology, 2018
Rouslan Kotchetkov, Erin Ellison
exaly  

Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies

Ca-A Cancer Journal for Clinicians, 2018
Chandrajit P Raut, Mark W Grinstaff
exaly  

Novel-Targeted Therapy for Hematological Malignancies with JAK and HDAC Dual Inhibitors

Future Medicinal Chemistry, 2019
Hong Liu, Xuewu Liang
exaly  

Dual-target CAR-T cell therapy: A new strategy to improve the therapeutic effect of hematological malignancies

Critical Reviews in Oncology/Hematology
Hongmei Ning
exaly  

Dual-energy CT imaging of thoracic malignancies

Cancer Imaging, 2013
Long Jiang Zhang, Guang Ming Lu
exaly  

Clinical efficacy and safety of umbralisib, a dual PI3Kδ/CK1-ϵ inhibitor, in treatment of hematologic malignancies

Frontiers in Oncology
Hai-En Cheng
exaly